Cargando…

Soluble CD163 as a Potential Biomarker in Systemic Sclerosis

OBJECTIVE: To evaluate the performance of serum and urinary sCD163 concentrations as possible biomarker in systemic sclerosis (SSc). METHODS: Urine and serum samples were obtained from SSc patients and age- and sex-matched controls. Serum and urinary sCD163 concentrations were measured by commercial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frantz, Camelia, Pezet, Sonia, Avouac, Jerome, Allanore, Yannick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901934/ https://www.ncbi.nlm.nih.gov/pubmed/29805720 http://dx.doi.org/10.1155/2018/8509583

Ejemplares similares

Regulatory T Cells in Systemic Sclerosis
por: Frantz, Camelia, et al.
Publicado: (2018)

Targeting Costimulatory Pathways in Systemic Sclerosis
por: Boleto, Gonçalo, et al.
Publicado: (2018)

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2016)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis
por: Leblond, Agathe, et al.
Publicado: (2018)

Soluble CD 163: A novel biomarker
por: Ahuja, Rajeev B.
Publicado: (2011)

Soluble CD163 in intracerebral hemorrhage: biomarker for perihematomal edema
por: Roy‐O'Reilly, Meaghan, et al.
Publicado: (2017)

Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
por: Etzerodt, Anders, et al.
Publicado: (2017)

Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2015)

Retraction Note: Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis
por: Ruzehaji, Nadira, et al.
Publicado: (2023)

Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis
por: Stilund, Morten, et al.
Publicado: (2014)

T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
por: Boleto, Gonçalo, et al.
Publicado: (2018)

Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis
por: Cauvet, Anne, et al.
Publicado: (2023)

Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis
por: Avouac, Jérôme, et al.
Publicado: (2013)

Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD163 (sCD163) in Sepsis, a Prospective Study
por: Feng, Lin, et al.
Publicado: (2012)

Soluble CD163: A novel biomarker for the susceptibility to sepsis in severe burn injuries
por: Piatkowski, Andrzej, et al.
Publicado: (2011)

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis
por: Huang, Yun-Ju, et al.
Publicado: (2022)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2013)

Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients with Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel
por: Stilund, Morten, et al.
Publicado: (2015)

Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss
por: Xie, Peilin, et al.
Publicado: (2022)

Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française
por: Combier, Alice, et al.
Publicado: (2021)

Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis
por: Huang, Yun-Ju, et al.
Publicado: (2022)

Soluble ST2 and CD163 as Potential Biomarkers to Differentiate Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
por: Gao, Zhuo, et al.
Publicado: (2019)

Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models
por: Orvain, Cindy, et al.
Publicado: (2022)

Circulating Soluble CD163: A Potential Predictor for the Functional Outcome of Acute Ischemic Stroke
por: Sun, Houchao, et al.
Publicado: (2021)

Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis
por: Zhang, Yue, et al.
Publicado: (2021)

Soluble CD163-Associated Dietary Patterns and the Risk of Metabolic Syndrome
por: Hu, Tzu-Yu, et al.
Publicado: (2019)

Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease
por: Azuma, Yoshihiro, et al.
Publicado: (2020)

Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models
por: Elhai, Muriel, et al.
Publicado: (2015)

Urinary soluble CD163 as a biomarker of disease activity and relapse in antineutrophil cytoplasm antibody-associated glomerulonephritis
por: Villacorta, Javier, et al.
Publicado: (2020)

Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study
por: David, Clémence, et al.
Publicado: (2022)

CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients
por: Greco, Rosaria, et al.
Publicado: (2021)

Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis
por: Kawanaka, Miwa, et al.
Publicado: (2023)

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
por: Gantzel, Rasmus Hvidbjerg, et al.
Publicado: (2021)

Soluble CD163 Identifies Those at Risk for Increased Hepatic Inflammation & Fibrosis
por: Sherman, Kenneth E, et al.
Publicado: (2021)

Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance
por: Dereke, Jonatan, et al.
Publicado: (2019)

The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects
por: Cairoli, Victoria, et al.
Publicado: (2022)

Soluble CD163 as a biomarker of periodontal disease – A biochemical study using enzyme-linked immunosorbent assay
por: Sai, Karthikeyan S. S., et al.
Publicado: (2020)

CD163 as a Biomarker in Colorectal Cancer: The Expression on Circulating Monocytes and Tumor-Associated Macrophages, and the Soluble Form in the Blood
por: Krijgsman, Daniëlle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k1nqlul92u9tcdb94hfscff2ue